Causal Relationship Between Immune Cell Signatures and Colorectal Cancer: a Bi-directional, Two-sample Mendelian Randomization Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Mar 3

PMID 40033246

Authors

Ruizhi Liu

Liansha Tang

Yunjia Liu

Handan Hu

Jiyan Liu

Affiliations

Soon will be listed here.

Abstract

Background: Prior studies have demonstrated the association between immune cells and colorectal cancer (CRC). However, the causal link to specific immunophenotypes is limited. This study intends to elucidate the causal relationship of immune cell signatures on CRC.

Methods: We performed a bi-directional and two-sample mendelian randomization (MR) study, utilizing GWAS summary data of 731 immune cell traits (n = 3,757) and CRC statistics (n = 470,002). The primary MR methodology was inverse-variance weighted (IVW) method. Furthermore, heterogeneity was evaluated by Cochran's Q test. MR-PRESSO and MR-Egger were employed to assess horizontal and vertical pleiotropy respectively. Sensitivity analysis and FDR correction were conducted in our results. These results were validated in both the UK Biobank and FinnGen cohorts. We also extracted transcriptomic data of CRC and adjacent non-tumor tissues from TCGA, and used CIBERSORT to compare the infiltration patterns of 22 immune cell panels between normal tissues and the tumor microenvironment (TME).

Results: Our study indicated nine immune cell signatures had significant causality with the risk of CRC after sensitivity analysis and FDR correction. The positive results covered four panels: B cell, CD8 + T cell, Treg, and monocyte. IgD- CD38br and IgD + CD38br B cell, CD8dim and CD28 + CD45RA- CD8dim T cell, and CD14 on CD14 + CD16- monocyte were the protective factors of CRC. However, CD39 + resting Treg, CX3CR1 on CD14- CD16 + monocyte, FSC-A on HLA DR + T cell, and BAFF-R on B cell increased the risk of CRC. The results were validated in the UK Biobank data and FinnGen cohorts. The data from the TCGA database also confirmed the infiltration of B cell, CD8 + T cell, Treg, and monocyte panels in the TME.

Conclusion: This study highlights the causal link between specific immune cell phenotypes and CRC, providing valuable insights into the immune microenvironment's role in CRC. The validation of our findings using large-scale datasets (UK Biobank, FinnGen) and TCGA underscores the robustness of our results, offering new potential therapeutic targets for CRC treatment.

References

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Guo L, Wang C, Qiu X, Pu X, Chang P . Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. Front Immunol. 2020; 11:1052. PMC: 7270196. DOI: 10.3389/fimmu.2020.01052. View

Tarlinton D . B-cell memory: are subsets necessary?. Nat Rev Immunol. 2006; 6(10):785-90. DOI: 10.1038/nri1938. View

Chambers A, Dixon S, White P, Williams A, Thomas M, Messenger D . Demographic trends in the incidence of young-onset colorectal cancer: a population-based study. Br J Surg. 2020; 107(5):595-605. PMC: 7155067. DOI: 10.1002/bjs.11486. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Gevrey J, Isaac B, Cox D . Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J Immunol. 2005; 175(6):3737-45. DOI: 10.4049/jimmunol.175.6.3737. View

Kumari S, Shivam P, Hansa J, Jamal F, Singh M, Bimal S . CD8 but not CD8 cells positive to CD56 dominantly express KIR and are cytotoxic during visceral leishmaniasis. Hum Immunol. 2018; 79(8):616-620. DOI: 10.1016/j.humimm.2018.05.004. View

Vincent F, Saulep-Easton D, Figgett W, Fairfax K, Mackay F . The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013; 24(3):203-15. PMC: 7108297. DOI: 10.1016/j.cytogfr.2013.04.003. View

Bohne A, Grundler E, Knuttel H, Volkel V, Furst A . Impact of laparoscopic versus open surgery on humoral immunity in patients with colorectal cancer: a systematic review and meta-analysis. Surg Endosc. 2023; 38(2):540-553. PMC: 10830603. DOI: 10.1007/s00464-023-10582-0. View

10.

Zhang J, Yan B, Liu J, Wang W . Action of circulating and infiltrating B cells in the immune microenvironment of colorectal cancer by single-cell sequencing analysis. World J Gastrointest Oncol. 2024; 16(6):2683-2696. PMC: 11236258. DOI: 10.4251/wjgo.v16.i6.2683. View

11.

Esensten J, Helou Y, Chopra G, Weiss A, Bluestone J . CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016; 44(5):973-88. PMC: 4932896. DOI: 10.1016/j.immuni.2016.04.020. View

12.

Dwyer K, Deaglio S, Gao W, Friedman D, Strom T, Robson S . CD39 and control of cellular immune responses. Purinergic Signal. 2008; 3(1-2):171-80. PMC: 2096766. DOI: 10.1007/s11302-006-9050-y. View

13.

Revilla S, Kranenburg O, Coffer P . Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Front Immunol. 2022; 13:903564. PMC: 9304750. DOI: 10.3389/fimmu.2022.903564. View

14.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

15.

Hull M . Nutritional prevention of colorectal cancer. Proc Nutr Soc. 2020; 80(1):59-64. DOI: 10.1017/S0029665120000051. View

16.

Pietropaolo G, Scarno G, Stabile H, Grimaldi A, Gismondi A, Santoni A . NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data. Mol Aspects Med. 2021; 80:100967. DOI: 10.1016/j.mam.2021.100967. View

17.

Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T . Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021; 6(1):72. PMC: 7896069. DOI: 10.1038/s41392-020-00449-4. View

18.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

19.

Li S, Martin A . Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored. Trends Mol Med. 2016; 22(4):274-289. DOI: 10.1016/j.molmed.2016.02.003. View

20.

Sanz I, Wei C, Lee F, Anolik J . Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008; 20(1):67-82. PMC: 2440717. DOI: 10.1016/j.smim.2007.12.006. View